Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2011-08-09
2011-08-09
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
active
07994223
ABSTRACT:
The invention relates to novel amide derivatives that are positive allosteric modulators of neuronal nicotinic receptors, compositions comprising the same, processes for preparing such compounds, and methods for using such compounds and compositions.
REFERENCES:
patent: 6057371 (2000-05-01), Glennon
patent: 7160876 (2007-01-01), Ji et al.
patent: 2004/0220247 (2004-11-01), Keitz et al.
patent: 2005/0065178 (2005-03-01), Basha et al.
patent: 2005/0137204 (2005-06-01), Ji et al.
patent: 2005/0245531 (2005-11-01), Ji et al.
patent: 521365 (1993-01-01), None
patent: WO0116097 (2001-03-01), None
patent: WO2004029053 (2004-04-01), None
patent: WO2007105814 (2007-09-01), None
patent: WO2008039489 (2008-04-01), None
“Pain,” Merck Manuals Online Medical Library: Home Edition. Accessed Mar. 24, 2009. <http://www.merck.com/mmhe/sec06/ch078/ch078a.html>.
Stillman, Mark. “Clinical approach to patients with neuropathic pain.” Cleveland Clinic Journal of Medicine, 73 (8), pp. 726-730, 733-739.
Ettmayer et al. “Lessons Learned from Marketed and Investigational Prodrugs.” J. Med. Chem., (2004), 47(10): 2393-2404.
Stella, Valentino. “Prodrugs as therapeutics.” Expert Opin. Ther. Patents (2004), 14(3): 277-280.
Testa, Bernard. “Prodrug research: futile or fertile?” Biochemical Pharmacology, 68 (2004): 2097-2106.
Wolff et al. Burger's Medicinal Chemistry and Drug Discovery. 5th ed. vol. 1: Principles and Practice. pp. 975-977.
Acklin, P. et al. , “5-aminomethylquinoxaline-2,3-diones, Part III: Arylamide derivatives as highly potent and selective glycine-site NMDA receptor antagonists,” Bioorganic & Medicinal Chemistry Letters, vol. 8 No. 5, pp. 493-498 , 1998.
Adler et al., “Schizophrenia, sensory gating, and nicotinic receptors,” Schizophrenia Bulletin , vol. 24 (2), pp. 189-202, 1998.
Adler, L. E. et al., Biol. Psychiatry, vol. 21, pp. 787-798, 1986.
Albuquerque et al., “Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease,” Alzheimer Dis. Assoc. Disord, vol. 15 Suppl 1, pp. s19-s25, 2001.
Alkondon, et al., “The nicotinic acetylcholine receptor subtypes and their function in the hippocampus and cerebral cortex”, Prog. Brain Res., 2004, 145, 109-120.
Balbani A., et al., “Recent developments for smoking cessation and treatment of nicotine dependence”, Expert. Opin. Ther. Pat., 2007, 17 (3), 287-297.
Bitner et al., “Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways,” J. Neurosci., 2007, vol. 27 (39), pp. 10578-10587.
Bowen, M.D., et al., Mol. Neuropharmacol., vol. 3, pp. 117-126, 1993.
Briggs, C.A. et al.,“Human a 7 Nicotinic Acetylcholine Receptor Responses to Novel Ligands”Neuropharmacology, vol. 34, pp. 583-590, 1995.
Briggs, C.A., et al., “Activation and inhibition of the human alpha7 nicotinic acetylcholine receptor by agonists,” Neuropharmacology, vol. 37, pp. 1095-1102 , 1998.
Broad L. M., et al., “Selective alpha7 nicotinic acetylcholine receptor ligands for the treatment of neuropsychiatric diseases”, Drugs of the Future, 2007, 32 (2), 161-170.
Bunnelle, W.H., et al., Exp. Opin. Ther. Patents, vol. 13(7), pp. 1003-1021, 2003.
Connolly, P.M., et al. Brain Res, vol. 992 (1) , pp. 85-95, 2003.
European Search Report dated Nov. 25, 2009 for EP09156652.
International Search Report for PCT/US2009/038474 dated Nov. 24, 2009.
Cordero-Erausquin et al. , “Tonic nicotinic modulation of serotoninergic transmission in the spinal cord,” PNAS, vol. 98 (5), pp. 2803-2807, 2001.
Couturier S., et al., “A Neuronal Nicotinic Acetylcholine Receptor Subunit (alpha7) Is Developmentally Regulated and forms a Homo-Oligomeric Channel Blocked by alpha-BTX”, Neuron, 1990, 5, 847-856.
Dajas Bailador F., et al., “Nicotinic acetylcholine receptors and the regulation of neuronal signalling”, Trends in Pharm. Sci., 2004, 25 (6), 317-324.
D'Andrea et al., “Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons,” Curr. Pharm. Des., vol. 12, pp. 677-684, 2006.
De Luca V., et al., “Regulation of alpha7-nicotinic receptor subunit and alpha7-like gene expression in the prefrontal cortex of patients with bipolar disorder and schizophrenia”, Acta Psychiatr. Scand., 2006, 114, 211-215.
Decker M. W., et al., “The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control”, Expert Opin. Investig. Drugs, 2001, 10 (10), 1819-1830.
Dunlop, J. et al., “In vitro screening strategies for nicotinic receptor ligands,” Biochemical Pharmacology, vol. 74 No. 8, pp. 1172-1181, 2007.
Ettmayer, Peter “Lessons Learned from Marketed and Investigational Prodrugs”, Medicinal Chemistry, 2004, vol. 47—Issue 10, 2393-2404.
Faghih, R. et al., “Advances in the Discovery of Novel Positive Allosteric Modulators of the alpha7 Nicotinic Acetylcholine Receptor,” Recent patent on CNS Drug Disc., vol. 2 (2) , pp. 99-106, 2007.
Friedman et al., “A double blind placebo controlled trial of donepezil adjunctive treatment to risperidonc for the cognitive impairment of schizophrenia,” Biol. Psychiatry, vol. 51, pp. 349-357, 2002.
Furniss B. S. et al, “Practical Organic Chemistry”, 5th Ed., Longman Scientific & Technical & John Wiley & Sons, Inc., Table of Contents, 1989.
Ganapathy, M.E., et al., J. Pharmacol. Exp. Ther., vol. 289, pp. 251-260, 1999.
Gotti Clementi,, “Neuronal nicotinic receptors: from structure to pathology”, Progress in Neurobiology, 2004, 74, 363-396.
Gotti, et al., “Brain neuronal nicotinic receptors as new targets for drug discovery,” Curr. Pharm. Des. , vol. 12, pp. 407-428, 2006.
Greene T.W., et al., “Protection for the Amino group,” Protective Groups in Organic Synthesis, 1999, Edition 3, John Wiley & Sons, 494-653.
Gundish D.,, “Nicotinic acetylcholine receptor ligands as potential therapeutics”, Expert Opin. Ther. Patents, 2005, 15 (9), 1221-1239.
Gurwitz D.,, “The therapeutic potential of nicotine and nicotinic agonists for weight control”, Exp. Opin. Invest. Drugs, 1999, 8 (6), 747-760.
Hevers, W. Luddens, H., “The Diversity of GABA, Receptors,” Molec.. Neurobiol., vol. 18, pp. 35-86, 1998.
Higuchi T., et al., “Pro-drugs as Novel Delivery Systems,” Bioreversible Carriers in Drug Design, 1987, 14, American Pharmaceutical Association and Pergamon Press.
Hogg, et al.,, “Nicotinic acetylcholine receptors: From structure to brain function”, Rev. Physiol Biochem. Pharmacol., 2003, 147, 1-46.
Holladay et al., “Neuronal Nicotinic Acetylcholine Receptors as Targets for Drug Discovery,” J. Med. Chem., vol. 40 (26), pp. 4169-4194, 1997.
Hunter et al., “A novel nicotinic against facilitates induction of long-term potentiation in the rat hippocampus,” Neurosci. Lett., vol. 168, pp. 130-134, 1994.
Hurst et al., “A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization,” J. Neurosci. , vol. 25 (17), pp. 4396-4405, 2005.
IUPAC Commission on Nomenclature of Organic Chemistry: Rules for the Nomenclature of Organic Chemistry Section E: Stereochemistry, Pure Appl Chem, 1976, 45, 11-30.
Jonnala, et al. “Relationship between the increased cell surface .alpha.7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists”, Journal of Neuroscience Research, 2001, 66, 565-572.
Keller, et al. “Performance of alpha7 nicotinic receptor null mutants is impaired in appetitive learning measured in a signaled nose po
Clapham Bruce
Lee Chih-Hung
Mortell Kathleen H.
Nersesian Diana L.
Schrimpf Michael R.
Abbott Laboratories
Anderson Rebecca
Gettel Nancy J.
Holland Antonia M.
Otton Alicia L
LandOfFree
Amide derivatives as positive allosteric modulators and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amide derivatives as positive allosteric modulators and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amide derivatives as positive allosteric modulators and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2774801